Shore Capital Reiterates “House Stock” Rating for Poolbeg Pharma (LON:POLB)

Shore Capital reiterated their house stock rating on shares of Poolbeg Pharma (LON:POLB) in a report issued on Thursday,London Stock Exchange reports.

Poolbeg Pharma Price Performance

Poolbeg Pharma stock opened at GBX 4.20 ($0.05) on Thursday. The firm has a market cap of £21 million, a PE ratio of -420.00 and a beta of 2.11. The stock’s fifty day moving average price is GBX 7.51 and its two-hundred day moving average price is GBX 9.98. Poolbeg Pharma has a one year low of GBX 4.10 ($0.05) and a one year high of GBX 15.77 ($0.20).

About Poolbeg Pharma

Poolbeg Pharma plc is focussed on the development and commercialisation of innovative medicines targeting serious diseases with a high unmet medical need. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation.

Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value.